Physician profile
Alan Strumeyer
NPI 1952325821
$9,606.69
in general payments reported to CMS, 2019-2025
43 companies · $940 in 2025
The $940 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,228 · 2020: $885 · 2021: $1,475 · 2022: $982 · 2023: $1,314 · 2024: $1,783 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,370 · Travel and Lodging: $667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,370.07 |
| Travel and Lodging | $667.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,494.91 | 2021-2024 | Axonics, Bulkamid |
| Coloplast Corp | $921.55 | 2019-2025 | Titan |
| Endo Pharmaceuticals INC. | $874.17 | 2019-2023 | Xiaflex |
| Boston Scientific Corporation | $864.04 | 2019-2025 | Ams 700 |
| Janssen Biotech, INC. | $540.49 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $471.64 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $399.33 | 2021-2025 | Myrisk, Prolaris |
| Astellas Pharma US INC | $374.30 | 2019-2025 | Xtandi |
| Antares Pharma, INC. | $311.69 | 2019-2022 | |
| Procept Biorobotics Corporation | $282.62 | 2019-2022 | |
| Urogen Pharma, INC. | $256.69 | 2021-2025 | Jelmyto |
| Abbvie INC. | $252.08 | 2019-2024 | Botox, Lupron Depot |
| Teleflex LLC | $226.02 | 2022-2023 | Urolift |
| Tolmar Pharmaceuticals, INC. | $194.23 | 2019-2021 | |
| Olympus America INC. | $189.86 | 2021-2025 | Itind System |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $181.00 | 2019-2021 | |
| Pfizer INC. | $176.13 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $169.49 | 2023-2024 | Gemtesa |
| Neotract INC. | $161.42 | 2019 | |
| Ferring Pharmaceuticals INC. | $148.20 | 2019-2024 | Adstiladrin |
| Clarus Therapeutics INC. | $134.50 | 2021 | |
| Aytu Biopharma, INC. | $131.10 | 2019 | |
| Baxter Healthcare | $125.00 | 2022 | |
| Hollister Incorporated | $90.78 | 2021-2023 | Vapro Pocket |
| 180 Medical, INC. | $72.43 | 2019-2021 | |
| Abc Home Medical Supply, INC. | $68.47 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $62.44 | 2019-2025 | Provenge |
| Merck Sharp & Dohme LLC | $59.32 | 2020-2022 | |
| Tolmar, INC. | $54.14 | 2023-2025 | Eligard |
| C. R. Bard, INC. & Subsidiaries | $45.14 | 2025 | Bard Urinary Drainage Bag, Bardex I.C. Criticore Foley Tray Bardex Temperature-Sensing Foley Catheter |
| Acerus Pharmaceuticals Corporation | $40.58 | 2020-2021 | |
| Endo USA, INC. | $36.57 | 2025 | Xiaflex |
| Myovant Sciences INC. | $36.11 | 2021 | |
| Progenics Pharmaceuticals, INC. | $22.43 | 2025 | |
| Bioprotect Medical, INC. | $20.25 | 2025 | Bioprotect Balloon Implant System |
| Azurity Pharmaceuticals, INC. | $18.33 | 2025 | Azmiro |
| Rochester Medical Corporation | $15.63 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.99 | 2021 | |
| Avadel Specialty Pharmaceuticals, LLC | $14.78 | 2019 | |
| Urovant Sciences INC | $14.45 | 2021 | |
| Amag Pharmaceuticals, INC. | $14.00 | 2019 | |
| Amgen INC. | $13.89 | 2019 | |
| Metuchen Pharmaceuticals | $11.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Strumeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.